💁🏽♀️It’s been a while since we revisited how much our #WordsMatter in medicine 🤔- HF in particular. As we close out 2025, we make a plea to our -#FunctionNotFailure community - let’s not use the word “stable” in HF. It’s a disservice to all 🤐
👀 out our We’ve Been Thinking page @JCardFail & the 🔥 Dec issue :
https://t.co/NGIYXseJcx
I tell my patients who come see us at our Haverty Cardiometabolic Center, “the a.fib is the tip of the iceberg, and what’s below the surface is driven mostly by the metabolic disease of obesity.” - which drives the HTN, DM, inflammation, HFpEF, etc.
In HFpEF, comorbidities are common and associated with higher mortality
SGLT2i therapy use associated with attenuated risks
Comorbidity Patterns and Mortality in HFpEF: A Retrospective Longitudi... https://t.co/jzWCjMoC1Q
The Jefferson takeover continues @HFSA with our own Dr. J. Eduardo Rame delivering a blockbuster analysis of outcomes in the MOMENTUM-3 trial!
@HFSA#HFSA2025
A 50 male no other pmh recent awstemi presents for 3 months follow up with EF improvement from 20 to 40%. No other medical conditions. He is a professional sky diver and wants to return to work. What do you advise? @JasonKatzMD@AHajduczok@docbhardwaj@shelleyhallmd@KiranKhush1